Elicio Therapeutics disclosed that analysis of a subset of patients in its ongoing Phase 2 AMPLIFY‑7P trial showed antigen spreading to non‑mKRAS neoantigens in 13 of 15 patients, an 87 % rate. The finding was derived from ex vivo Fluorospot and intracellular cytokine staining assays performed on 5–12 tumor neoantigens per patient, demonstrating T‑cell responses against antigens not included in the ELI‑002 7P formulation.
The 87 % antigen‑spreading rate complements the 99 % mKRAS‑specific response rate reported for the same cohort, indicating that the AMP platform not only elicits a robust targeted response but also broadens the immune repertoire. The breadth of T‑cell activity suggests a more durable anti‑tumor effect, as the immune system can recognize and attack a wider array of tumor‑specific antigens, reducing the likelihood of immune escape.
Elicio’s Phase 2 trial evaluates ELI‑002 7P in patients with mKRAS‑driven pancreatic cancer. The antigen‑spreading data reinforce the platform’s design to deliver immunotherapeutics to lymph nodes, a strategy that has now shown tangible evidence of broader immune activation. If the broader response translates into improved clinical outcomes, the therapy could benefit a larger patient population beyond those with the seven target KRAS mutations.
The company expects the final disease‑free survival analysis for the AMPLIFY‑7P trial in the fourth quarter of 2025 or the first half of 2026. The antigen‑spreading results strengthen confidence in the trial’s potential to demonstrate meaningful survival benefits, which could accelerate regulatory and commercial milestones.
CEO Robert Connelly said the data “strengthen the robust immunogenicity and HLA data we have previously shared for our Phase 2 trial” and that the induction of personalized neoantigen‑specific T cells could enhance the effectiveness of ELI‑002 7P by expanding immune recognition across multiple tumor antigens.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.